SCHEDULE: TransCode Therapeutics Amends CVR, Preferred Stock Terms

TransCode Therapeutics, Inc. has amended its Contingent Value Rights Agreement and the terms of its Series A and B Preferred Stock, impacting conversion limitations and delisting provisions.

Summary

• A Contingent Value Rights (CVR) Agreement was established effective October 8, 2025, entitling common stockholders as of October 20, 2025, to one CVR per share.
• Each CVR entitles holders, in aggregate, to 50% of Net Proceeds from any Upfront Payment or Milestone Payment received by the Company over a seven-year term, distributed quarterly, subject to deductions.
• The Certificate of Designation for Series A and Series B Preferred Stock was amended on October 27, 2025, with consent from preferred holders and the Board of Directors.
• The amendment clarifies that the Company shall not issue more than an aggregate of 19.9% of the Common Stock outstanding as of October 8, 2025, from preferred stock conversion without stockholder approval, in accordance with Nasdaq listing rules.
• The amendment also removed the ability of a preferred stock holder to convert their preferred stock into common stock at their option in the event of a delisting from Nasdaq.
• No additional securities were issued or sold as a result of these amendments.

Sentiment

Score: 6

Explanation: The establishment of CVRs offers potential future upside for common shareholders, and the 19.9% conversion cap provides protection against immediate, unapproved dilution, which are positive aspects. However, the removal of the delisting conversion option for preferred holders is a negative for those specific investors, and the substantial potential future dilution from full preferred conversion remains a significant consideration.

Positives

• The establishment of Contingent Value Rights (CVRs) provides a potential future value stream for common stockholders from successful licensing or partnership deals.
• The amendment to cap common stock issuance from preferred stock conversion at 19.9% without shareholder approval protects existing common shareholders from immediate, significant dilution and ensures compliance with Nasdaq listing rules.

Negatives

• The removal of the preferred stock holders' option to convert their shares into common stock upon a Nasdaq delisting removes a protective clause for those investors, potentially increasing their risk.
• CVR distributions are subject to deductions for taxes and out-of-pocket expenses, which will reduce the net proceeds to holders.
• CVRs are generally non-transferable, limiting liquidity for holders.

Risks

• The value of CVRs is contingent on the Company achieving Upfront or Milestone Payments, which are uncertain and dependent on future strategic transactions and clinical success.
• A significant potential for future dilution exists, as 13,766,905 shares of common stock are issuable upon full conversion of Series A and B Preferred Stock, far exceeding the 916,968 common shares currently outstanding, with full conversion still subject to future shareholder approval.
• The removal of the delisting conversion option for preferred shareholders could negatively impact their investment in the event of a Nasdaq delisting.

Future Outlook

The CVR Agreement suggests a future strategy involving potential licensing or partnership deals that could generate upfront or milestone payments. The amendments to preferred stock terms indicate ongoing adjustments to the capital structure in anticipation of future events, potentially including a full conversion of preferred stock subject to shareholder approval.

Industry Context

Contingent Value Rights (CVRs) are commonly utilized in the biotech and pharmaceutical sectors, particularly in M&A or asset divestitures, to bridge valuation gaps and provide contingent value based on future clinical or regulatory milestones. The amendments to preferred stock terms reflect standard corporate governance practices and compliance with Nasdaq listing rules concerning convertible securities, specifically addressing potential dilution thresholds.

Comparison to Industry Standards

• The use of CVRs is a common mechanism in the biotech/pharma industry for distributing contingent payments from future asset performance or strategic transactions, allowing investors to participate in potential upside.
• The 19.9% conversion cap without shareholder approval is a standard compliance measure for Nasdaq-listed companies to prevent significant dilution from convertible securities without investor consent, aligning with typical market practices.
• The removal of a delisting conversion option for preferred stock is less common as it removes a protective feature for investors, but could be part of broader renegotiations or reflect the company's current financial position relative to its capital providers.

Corporate Governance

Stakeholder Impact

• Shareholders (Common): Potential future value from CVRs; protection from immediate, unapproved dilution from preferred stock conversion (due to 19.9% cap).
• Shareholders (Preferred): Loss of a protective conversion option in case of Nasdaq delisting.
• Company: Enhanced compliance with Nasdaq listing rules; structured mechanism for distributing future contingent payments.

Next Steps

• The Company will likely pursue strategic transactions (e.g., licensing, partnerships) to generate Upfront or Milestone Payments that would trigger CVR distributions.
• Future shareholder approval will be required for the full conversion of Preferred Stock exceeding the 19.9% threshold, which could lead to significant dilution.

Key Dates

Recommendation

The filing presents a mixed bag of structural changes. The CVRs offer potential future upside, which is a positive, but the value is contingent and uncertain. The 19.9% conversion cap for preferred stock is a positive for common shareholders as it prevents immediate, significant dilution without their approval, aligning with Nasdaq rules. However, the sheer volume of preferred shares convertible into common stock (over 13.7 million vs. 916,968 outstanding common shares) represents a massive potential future dilution event that still looms, subject to shareholder approval. The removal of the delisting conversion option for preferred holders is a negative for those investors. Given these offsetting factors and the contingent nature of the CVRs, a 'hold' recommendation is appropriate as investors await further clarity on the company's strategic transactions and future capital structure decisions.

Keywords

TransCode Therapeutics, Contingent Value Rights, CVR Agreement, Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, Nasdaq listing rules, Dilution, Beneficial Ownership, Schedule 13D Amendment